Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues

Background: HBeAg-negative chronic hepatitis B patients require long-term nucleos(t)ide analogues (NAs) because loss of surface antigen (HBsAg) is unusual. Low quantitative HBsAg (qHBsAg) levels can identify patients with higher probability of seroclearance. The aim of our study was to evaluate qHBs...

Descripción completa

Detalles Bibliográficos
Autores: Broquetas, Teresa|||0000-0002-5935-3076, Garcia-Retortillo, M.|||0000-0001-6783-7604, Hernandez, Juan José, Puigvehí, Marc|||0000-0002-3694-3241, Cañete Hidalgo, Nuria|||0000-0001-9501-7590, Coll, Susanna|||0000-0002-0395-9685, Cabrero, Beatriz, Giménez, Maria Dolors, Solà, Ricard|||0000-0002-8648-8179, Carrión Rodríguez, José Antonio|||0000-0001-7191-6081
Tipo de recurso: artículo
Fecha de publicación:2017
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:249579
Acceso en línea:https://ddd.uab.cat/record/249579
https://dx.doi.org/urn:doi:10.1371/journal.pone.0188303
Access Level:acceso abierto
Palabra clave:Adolescent
Adult
Aged
Antiviral Agents
Female
Hepatitis B e Antigens
Hepatitis B Surface Antigens
Hepatitis B, Chronic
Humans
Male
Middle Aged
Retrospective Studies
Young Adult
Descripción
Sumario:Background: HBeAg-negative chronic hepatitis B patients require long-term nucleos(t)ide analogues (NAs) because loss of surface antigen (HBsAg) is unusual. Low quantitative HBsAg (qHBsAg) levels can identify patients with higher probability of seroclearance. The aim of our study was to evaluate qHBsAg in HBeAg-negative patients receiving NAs to predict a reduction of HBsAg levels and seroclearance. Methods: Retrospective analysis of qHBsAg in HBeAg-negative patients before and at years 1, 3, 5, 8 and over of NAs treatment. Results: From 1999 to 2015, HBsAg was quantified in 358 serum samples from 95 HBeAg-negative patients. Low qHBsAg (<120 IU/mL) was identified at baseline or during follow-up in 14% of patients and HBsAg loss in 4%. No baseline variables predicted seroclearance and only treatment duration predicted low qHBsAg. The annual decline of qHBsAg was -0.102 log IU/ mL and the median time to HBsAg loss was 6.04 years. The decline was greater in patients achieving low HBsAg levels (-0.257) than in those who did not (-0.057)(p<0.001). The diagnostic accuracy (ROC curve, 95%CI) of qHBsAg delta at year 3 was 0.89 (0.81-0.97), with cut-off.

Similares en LA Referencia